CLP China Gold Fund led the investment, Sipai network completed 400 million D round of financing, focusing on cancer, special drugs to profitable development
Arterial Network was informed that in the fourth quarter of 2018, the integrated medical management technology company focused on tumors and special medicines, Sipai Network successfully completed the 400 million D round of financing within three months. This round of financing was led by CLP CICC, and CDH Investment and Investment, the existing shareholders Tencent, Fidelity's Stowe Capital and F-Prime, IDG Capital also further increased investment. In 2019, the company plans to carry out further capital operations to help business development. From 2014, Sipai Network immediately focused on the field of oncology and related special medicines. More than 100 core team members are from the medical, marketing and sales teams in the anti-tumor business field of multinational pharmaceutical companies. They have a deep understanding of this field and have With an average of 10 years of work experience and a very rich customer base. Ma Xuguang, the founder of Sipai Network, believes that only by focusing on doing things that are good for doctors and patients, and serving pharmaceutical innovation companies and insurance companies, will the mission of the school be completed, so that the tumor will no longer be a lifeblood. In order to achieve this mission, Sipai is rooted in real medical needs and creates two core advantages: 1) nationwide, accurate to the network of clinical oncologists in the specialist field; 2) comprehensive high-quality information flow in the field of cancer and special medicine. Based on these two advantages, the company has successfully built four high-speed development of large-scale business segments: Bisson Medical The only clinical laboratory management (SMO) focusing on the field of oncology special drugs in China. Bisson Medical has taken a leading position in the field of clinical trials for new drugs. It has won wide recognition from major multinational pharmaceutical companies, large local pharmaceutical companies, and leading emerging biotechnology companies. It has also won high recognition from hospital clinical bases and medical experts. Sipai Pharmacy Special Pharmacy (DTP) for Oncology and Special Diseases. Sipai Pharmacy insists on self-construction and centralized management, and establishes a unique pharmacy service, follow-up, and patient management system. Sipai Pharmacy has completed the layout of all major cities and hospitals, covering a total of 649 county-level cities (including). With the rapid development of the business, SIPA is also considering introducing new investors to support the expansion of pharmacy business and service upgrades. A number of strategic and financial investors have expressed strong interest. Sipai Health Health insurance control network. The development of commercial health insurance, medical management and control capabilities are the core. Based on its own medical data capabilities and the construction of a nationwide PPO (Oncology Excellence Expert Network), SI Pai Health helps major insurance companies design innovative products and provide patient-centered professional services. Established cooperative relationships with well-known companies such as raising, health, and reinsurance. Sipai Medical Technology The drug is listed in the full cycle management. Relying on the multi-layered data and physical network formed by the first three businesses, Sipai has cooperated with a number of multinational pharmaceutical companies to conduct a large number of real world research (RWE) and patient management, which has precipitated high-value clinical information analysis in an innovative way. Assisted several pharmaceutical companies in completing new drug-free clinical marketing and drug indications. The interaction of people flow, logistics, capital flow and information flow in the four businesses of Sipai is an effective framework for building an anti-tumor ecosystem. Sipai firmly believes that the service medical field must continue to be awe-inspiring and persevere in doing things. Sipa expects to work with all serious and professional partners to make the tumor no longer a life. Zhou Xuan, a partner of CLP China Gold Fund, said: "With the sincere efforts of the company's management and the help of the front-line investors, the company has become a benchmark in the industry, initially establishing a coverage of patients, oncologists, medical institutions. The closed-loop ecology of pharmaceutical companies and payers. The CLP Gold Fund is willing to give full play to our resource advantages and assist enterprises to further develop in various business segments to help the company grow profitably." Yao Leiwen, managing director of Tencent Investment, said that the company has focused on deepening the field of cancer in the past few years and continues to explore and extend its business direction. At present, the company's various businesses revolve around the true demands of doctors and patients, creating a solid incremental value. Tencent will continue to support the SI, to help the efficiency of all aspects of the medical system and promote industry progress. The D round of financing is expected to accelerate the growth of each business unit, thus promoting the overall profitability of the company. About CLP Gold Fund CLP Gold Fund is an industrial investment fund jointly operated by China Gold Capital Operation Co., Ltd. and China Electronic Information Industry Group Co., Ltd., focusing on advanced electronic information and big data industries. We're professional Endoscope Bridge
manufacturers and suppliers in China, specialized in providing high
quality medical instruments with reasonable price. We warmly welcome you
to buy or wholesale bulk Endoscope Bridge for sale here and get quotation from our factory. Endoscope Bridge,Cystoscopy Endoscope Bridge,Cystoscope Single Channel Bridge,Cystoscope Double Channel Bridge Tonglu WANHE Medical Instrument Co., Ltd , https://www.vanhurhealth.com